Should I buy or sell Reviva Pharmaceuticals stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Reviva Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" RVPH shares. View RVPH analyst ratings or view top-rated stocks .

What is Reviva Pharmaceuticals' stock price target for 2024?

4 analysts have issued twelve-month target prices for Reviva Pharmaceuticals' stock. Their RVPH share price targets range from $12.00 to $20.00. On average, they expect the company's stock price to reach $16.33 in the next twelve months. This suggests a possible upside of 1,092.2% from the stock's current price. View analysts price targets for RVPH or view top-rated stocks among Wall Street analysts .

How have RVPH shares performed in 2024?

Reviva Pharmaceuticals' stock was trading at $5.15 at the start of the year. Since then, RVPH shares have decreased by 73.4% and is now trading at $1.37. View the best growth stocks for 2024 here .

Are investors shorting Reviva Pharmaceuticals?

Reviva Pharmaceuticals saw a increase in short interest in May. As of May 15th, there was short interest totaling 1,780,000 shares, an increase of 42.4% from the April 30th total of 1,250,000 shares. Based on an average daily trading volume, of 303,800 shares, the short-interest ratio is presently 5.9 days. View Reviva Pharmaceuticals' Short Interest .

When is Reviva Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024. View our RVPH earnings forecast .

How were Reviva Pharmaceuticals' earnings last quarter?

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) announced its quarterly earnings results on Tuesday, May, 14th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.28) by $0.03.

Who are Reviva Pharmaceuticals' major shareholders?

Reviva Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (3.59%) and Torno Capital LLC (0.00%). Insiders that own company stock include Prabhu Narayan, Purav Patel and Vedanta Partners, Llc. View institutional ownership trends .

How do I buy shares of Reviva Pharmaceuticals?

Shares of RVPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:RVPH

Reviva Pharmaceuticals (RVPH) Stock Price, News & Analysis

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Free RVPH Stock Alerts

$1.37

0.00 (0.00%)

(As of 05/31/2024 ET)

Add

Compare

Today's Range: $1.36
▼
$1.39
50-Day Range: $1.31
▼
$3.90
52-Week Range: $1.21
▼
$8.00

Volume: 91,689 shs
Average Volume: 322,410 shs
Market Capitalization: $38.25 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $16.33

Reviva Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 1,092.2% Upside
$16.33 Price Target
Short Interest: Bearish
6.38% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.27
Based on 9 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.98) to ($0.90) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.90 out of 5 stars

Medical Sector

673rd out of 929 stocks

Pharmaceutical Preparations Industry

313th out of 438 stocks

3.5

Analyst's Opinion

Consensus Rating
Reviva Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Reviva Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.
Read more about Reviva Pharmaceuticals' stock forecast and price target.

1.0

Short Interest

Percentage of Shares Shorted
6.38% of the outstanding shares of Reviva Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
Reviva Pharmaceuticals has a short interest ratio ("days to cover") of 5.9.
Change versus previous month
Short interest in Reviva Pharmaceuticals has recently increased by 42.40%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Reviva Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Reviva Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for RVPH.

1.8

News and Social Media Coverage

News Sentiment
Reviva Pharmaceuticals has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.82 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 9 news articles for Reviva Pharmaceuticals this week, compared to 2 articles on an average week.
Search Interest
Only 1 people have searched for RVPH on MarketBeat in the last 30 days. This is a decrease of -86% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added Reviva Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Reviva Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
31.83% of the stock of Reviva Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
63.18% of the stock of Reviva Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.
Read more about Reviva Pharmaceuticals' insider trading history.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Reviva Pharmaceuticals are expected to grow in the coming year, from ($0.98) to ($0.90) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Reviva Pharmaceuticals is -0.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Reviva Pharmaceuticals is -0.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Read more about Reviva Pharmaceuticals' valuation and earnings.

See Top Rated MarketRank™ Stocks Here

Ad Weiss Ratings

The ONE AI Stock to own now. (It’s not Nvidia.)

Don’t panic — you haven’t missed the boat on AI. In fact, it has barely launched. Sure, the early stages of this boom were big … But I believe the real wealth in AI has yet to be made …

Click here to see the presentation now.

About Reviva Pharmaceuticals Stock (NASDAQ:RVPH)

Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. Reviva Pharmaceuticals Holdings, Inc. was founded in 2018 and is headquartered in Cupertino, California.

RVPH Stock Price History

30 days | 90 days | 365 days | Advanced Chart

RVPH Stock News Headlines

May 30 at 7:20 PM | prnewswire.com

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPH

May 29 at 6:10 PM | finance.yahoo.com

Reviva Announces Closing of $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

May 29 at 4:45 PM | globenewswire.com

Reviva Announces Closing of $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

May 28, 2024 | finance.yahoo.com

Reviva Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

May 28, 2024 | americanbankingnews.com

Reviva Pharmaceuticals (NASDAQ:RVPH) Rating Reiterated by Benchmark

May 28, 2024 | globenewswire.com

Reviva Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

May 23, 2024 | prnewswire.com

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPH

May 22, 2024 | finance.yahoo.com

RVPH: Enrollment Right Around the Corner

May 21, 2024 | globenewswire.com

Reviva to Participate in the BIO International Convention

May 20, 2024 | edition.cnn.com

Reviva Pharmaceuticals Holdings, Inc.

May 16, 2024 | prnewswire.com

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPH

May 15, 2024 | finance.yahoo.com

Reviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia

May 15, 2024 | globenewswire.com

Reviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia

May 14, 2024 | investorplace.com

RVPH Stock Earnings: Reviva Pharmaceuticals Beats EPS for Q1 2024

May 14, 2024 | globenewswire.com

Reviva Reports First Quarter 2024 Financial Results and Recent Business Highlights

May 13, 2024 | globenewswire.com

Reviva to Present New Preclinical Efficacy Data on Brilaroxazine in Idiopathic Pulmonary Fibrosis at 2024 ATS International Conference

May 10, 2024 | prnewswire.com

RVPH INVESTOR NOTICE: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Reviva Pharmaceuticals Holdings, Inc. Investors to Inquire About Securities Class Action Investigation - RVPH

May 9, 2024 | globenewswire.com

Reviva to Present New Non-Clinical Pharmacology Data on Brilaroxazine at the ASPET 2024 Annual Meeting

May 6, 2024 | prnewswire.com

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPH

May 4, 2024 | morningstar.com

Reviva Pharmaceuticals Holdings Inc Ordinary Shares RVPH

April 28, 2024 | prnewswire.com

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPH

April 28, 2024 | stockhouse.com

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPH

April 25, 2024 | finance.yahoo.com

RVPH: Full Year 2023 Results

April 25, 2024 | businesswire.com

RVPH LOSS ALERT: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Reviva Pharmaceuticals Holdings, Inc. Investors to Inquire About Securities Class Action Investigation – RVPH

April 22, 2024 | markets.businessinsider.com

Analysts Are Bullish on Top Healthcare Stocks: Reviva Pharmaceuticals Holdings (RVPH), Roivant Sciences (ROIV)

See More Headlines

Company Calendar

Last Earnings: 5/14/2024
Today: 5/31/2024
Next Earnings (Estimated): 8/12/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:RVPH
CUSIP: N/A
CIK: 1742927
Web: www.revivapharma.com
Phone: (408) 501-8881
Fax: N/A
Employees: 15
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $16.33
High Stock Price Target: $20.00
Low Stock Price Target: $12.00
Potential Upside/Downside: +1,092.2%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.59)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-39,260,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -3,409.55%
Return on Assets: -294.65%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.93
Quick Ratio: 0.93

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.05) per share
Price / Book: -27.40

Miscellaneous

Outstanding Shares: 27,919,000
Free Float: 19,032,000
Market Cap: $38.25 million
Optionable: Optionable
Beta: 0.05

Key Executives

Dr. Laxminarayan Bhat Ph.D. (Age 59)
Founder, CEO, President & Director
Comp: $450k
Mr. Narayan Prabhu (Age 52)
Chief Financial Officer
Comp: $325k

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

RVPH Stock Analysis - Frequently Asked Questions

Should I buy or sell Reviva Pharmaceuticals stock right now?: 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Reviva Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" RVPH shares.
View RVPH analyst ratings or view top-rated stocks.
What is Reviva Pharmaceuticals' stock price target for 2024?: 4 analysts have issued twelve-month target prices for Reviva Pharmaceuticals' stock. Their RVPH share price targets range from $12.00 to $20.00. On average, they expect the company's stock price to reach $16.33 in the next twelve months. This suggests a possible upside of 1,092.2% from the stock's current price.
View analysts price targets for RVPH or view top-rated stocks among Wall Street analysts.
How have RVPH shares performed in 2024?: Reviva Pharmaceuticals' stock was trading at $5.15 at the start of the year. Since then, RVPH shares have decreased by 73.4% and is now trading at $1.37.
View the best growth stocks for 2024 here.
Are investors shorting Reviva Pharmaceuticals?: Reviva Pharmaceuticals saw a increase in short interest in May. As of May 15th, there was short interest totaling 1,780,000 shares, an increase of 42.4% from the April 30th total of 1,250,000 shares. Based on an average daily trading volume, of 303,800 shares, the short-interest ratio is presently 5.9 days.
View Reviva Pharmaceuticals' Short Interest.

When is Reviva Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024.
View our RVPH earnings forecast.
How were Reviva Pharmaceuticals' earnings last quarter?: Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) announced its quarterly earnings results on Tuesday, May, 14th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.28) by $0.03.
Who are Reviva Pharmaceuticals' major shareholders?: Reviva Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (3.59%) and Torno Capital LLC (0.00%). Insiders that own company stock include Prabhu Narayan, Purav Patel and Vedanta Partners, Llc.
View institutional ownership trends.
How do I buy shares of Reviva Pharmaceuticals?: Shares of RVPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:RVPH) was last updated on 6/1/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Get Started with MarketBeat

	Read Your Daily Newsletter
	Check Out My MarketBeat
	Watch Our Tutorial Videos
	Add a Stock to Your Watchlist
	Set Up an Instant Alert
	View a Company's Profile Page
	View Our Financial Calendars
	View Today's Analyst Ratings

Reviva Pharmaceuticals (RVPH) Stock Price, News & Analysis

Reviva Pharmaceuticals MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Consensus Rating

Amount of Analyst Coverage

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Dividend Yield

Dividend Growth

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Insider Buying vs. Insider Selling

Percentage Held by Insiders

Percentage Held by Institutions

Earnings and Valuation

Earnings Growth

Price to Earnings Ratio vs. the Market

Price to Earnings Ratio vs. Sector

About Reviva Pharmaceuticals Stock (NASDAQ:RVPH)

RVPH Stock Price History

RVPH Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

RVPH Stock Analysis - Frequently Asked Questions

Overall MarketRank^™